Anika Therapeutics

Anika Therapeutics products

Cingal
Indication: Osteoarthritis (OA) knee pain management—combines hyaluronic acid (for long-term lubrication) with a corticosteroid (for rapid anti-inflammatory relief)
Status: Approved and commercialized internationally; U.S. approval in progress

Integrity Implant System
Description: Hyaluronic acid-based, porous knitted scaffold (with PET reinforcement) for augmenting tendon repairs—e.g., rotator cuff, Achilles, peroneal tendon
Indication: Regenerative tendon repair augmentation
Status: Fully launched in the U.S.

Monovisc
Indication: Single-injection hyaluronic acid treatment for OA-related knee pain—provides up to six months of relief
Status: Approved and marketed in the U.S. and globally

NanoFx
Description: Microfracture-supporting regenerative solution for cartilage repair
Indication: Enhances cartilage healing post-microfracture
Status: Part of regenerative solutions portfolio

Orthovisc
Indication: Multi-injection hyaluronic acid viscosupplement for OA knee pain—effective for up to six months
Status: Approved and marketed in the U.S. and globally

Orthovisc mini
Indication: Smaller-volume version of Orthovisc for OA knee pain
Status: Marketed product—part of OA pain management lineup

Orthovisc-T
Description: Extended-duration hyaluronic acid viscosupplement variant of Orthovisc
Indication: OA knee pain management
Status: Marketed product

Hyalofast
Description: Off-the-shelf, 100% hyaluronic acid scaffold for cartilage repair, supporting hyaline-like regeneration
Indication: Cartilage repair in joint preservation
Status: Approved and sold in over 35 countries; U.S. launch targeted

Tactoset
Description: Hyaluronic acid-enhanced, injectable and settable calcium phosphate bone substitute
Indication: Augmentation in treating insufficiency fractures and in surgical hardware (e.g., suture anchors)
Status: Approved and launched

NanoFx (already listed under regenerative solutions as cartilage support)